Extended Abstracts
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx?/Doxil
R.A. Hilger, H. Richly, M. Grubert, C. Oberhoff, D. Strumberg, M.E. Scheulen and S. Seeber
Price
42.00 $
Volume 43 p. 588 - 589
Abstract
R.A. Hilger, H. Richly, M. Grubert, C. Oberhoff, D. Strumberg, M.E. Scheulen and S. Seeber
Extended Abstracts
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006
R.A. Hilger, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 42 p. 648 - 649
Abstract
R.A. Hilger, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation
R.A. Hilger, J. Baumgart, M.E. Scheulen, R. Trenschel, D. Strumberg, S. Seeber and D.W. Beelen
Price
42.00 $
Volume 42 p. 654 - 655
Abstract
R.A. Hilger, J. Baumgart, M.E. Scheulen, R. Trenschel, D. Strumberg, S. Seeber and D.W. Beelen
Extended Abstracts
Circadian rhythm in the regulation of the MAP kinase pathway – pitfall in the determination of surrogate parameters?
R.A. Hilger, D. Díaz-Carballo, S. Bauer, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 614 - 615
Abstract
R.A. Hilger, D. Díaz-Carballo, S. Bauer, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006
M. Heim, M. Sharifi, R.A. Hilger, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 616 - 617
Abstract
M. Heim, M. Sharifi, R.A. Hilger, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, S. Kredtke, D. Voliotis, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 620 - 621
Abstract
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, S. Kredtke, D. Voliotis, M.E. Scheulen, S. Seeber and D. Strumberg
2008 CESAR: Annual Meeting – Extended Abstracts
Preface – Combining clinical, translational and basic cancer drug research: The 2008 CESAR annual meeting
J. Brockmöller, D. Sehrt, and M.E. Scheulen
Price
42.00 $
Volume 47 p. 30 - 32
Abstract
J. Brockmöller, D. Sehrt, and M.E. Scheulen
2008 CESAR: Annual Meeting – Extended Abstracts
Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™/Doxil<sup>®</sup> in patients with hematological tumors
H. Richly, M. Grubert, M.E. Scheulen and R.A. Hilger
Price
42.00 $
Volume 47 p. 55 - 57
Abstract
H. Richly, M. Grubert, M.E. Scheulen and R.A. Hilger
2008 CESAR: Annual Meeting – Extended Abstracts
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors
M.M. Henke, H. Richly, A. Drescher, M. Grubert, D. Alex, D. Thyssen, U. Jaehde, M.E. Scheulen and R.A. Hilger
Price
42.00 $
Volume 47 p. 58 - 60
Abstract
M.M. Henke, H. Richly, A. Drescher, M. Grubert, D. Alex, D. Thyssen, U. Jaehde, M.E. Scheulen and R.A. Hilger
2008 CESAR: Annual Meeting – Extended Abstracts
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis
R.A. Hilger, H. Richly, M. Grubert, S. Kredtke, D. Thyssen, W. Eberhardt, J. Hense, M. Schuler and M.E. Scheulen
Price
42.00 $
Volume 47 p. 61 - 64
Abstract
R.A. Hilger, H. Richly, M. Grubert, S. Kredtke, D. Thyssen, W. Eberhardt, J. Hense, M. Schuler and M.E. Scheulen
2008 CESAR: Annual Meeting – Extended Abstracts
Pharmacokinetic study of S-1
B. Mende, J. Krauss, D. Thyssen, S. Kredtke, M.E. Scheulen, D. Strumberg, A. Hanauske, L. Makris, P. Scigalla, P.D. Urrea and R.A. Hilger
Price
42.00 $
Volume 47 p. 65 - 67
Abstract
B. Mende, J. Krauss, D. Thyssen, S. Kredtke, M.E. Scheulen, D. Strumberg, A. Hanauske, L. Makris, P. Scigalla, P.D. Urrea and R.A. Hilger
Extended Abstract
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006
R.A. Hilger, S. Kredke, D. Hedley, J.G. Moeller, R.J. Bauer, W. Stellberg, S. Seeber, M.E. Scheulen and D. Strumberg
Price
42.00 $
Volume 40 p. 567 - 568
Abstract
R.A. Hilger, S. Kredke, D. Hedley, J.G. Moeller, R.J. Bauer, W. Stellberg, S. Seeber, M.E. Scheulen and D. Strumberg
Extended Abstract
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors
D. Strumberg, D. Voliotis, J.-G. Moeller, R.A. Hilger, H. Richly, S. Kredtke, C. Beling, M.E. Scheulen and S. Seeber
Price
42.00 $
Volume 40 p. 580 - 581
Abstract
D. Strumberg1, D. Voliotis2, J.-G. Moeller2, R.A. Hilger1, H. Richly1, S. Kredtke1, C. Beling1, M.E. Scheulen1 and S. Seeber1
Clinical Pharmacology of P-glycoprotein and related transporters
Simultaneous measurement of cellular P-glycoprotein content and function by multiparametric flow-cytometry
M.R. Müller, K. Lennartz, B. Baack, M.M.E. Heim, S. Seeber and M.E. Scheulen
Price
42.00 $
Volume 38 p. 180 - 186
Abstract
M.R. Müller1, K. Lennartz2, B. Baack1, M.M.E. Heim1, S. Seeber1 and M.E. Scheulen1
1Department of Internal Medicine (Cancer Research) and 2Institute of Cell Biology (Cancer Research) (IFZ), West German Cancer Centre Essen, University of Essen Medical School, Essen, Germany
Objective: A multiparametric approach was applied to simultaneously determine expression and function of the drug efflux pump P-glycoprotein (PGP) in multidrug-resistant (MDR) human leukemic lymphoblast cell lines and isolated leukemic blasts using flow-cytometry in a patient with acute myeloid leukemia (AML). Methods: The antigen was measured by staining PGP using the monoclonal antibody 4e3 which does not inhibit the function of PGP. The 4e3 antibody binds to an external epitope of PGP and can therefore be used for staining living cells. Drug transport, mediated by PGP, was determined simultaneously by measuring rhodamine 123 (rho123) efflux. The MDR cell lines, CEM/VLB10-2 and CEM/VBL100 are 10-fold and 270-fold resistant to vinblastine (VBL), respectively, compared to the human PGP-negative parent cell line CEM/ WT and they express different amounts of PGP. Initially, living cells were stained using the 4e3 antibody and a secondary antibody labeled with 7-amino-4-methylcoumarin-3-acetic acid (AMCA). Cells were then incubated for 60 min with rho123 (10 mM) and analyzed for rhodamine and AMCA-derived fluorescence. The decrease in rho123 fluorescence was determined after a further period of 30 min. Results: CEM/VLB100 cells expressed larger amounts of PGP, and rho123 fluorescence after 30 min was 85% lower than the parent cell line. PGP expression and rho123 efflux were also detected in CEM/VLB10-2 cells which display a low degree of resistance, thus reflecting the high sensitivity of this method. PGP-expressing blasts and moderate rho123 efflux were also observed in a specimen derived from a patient with clinically resistant acute myeloid leukemia (AML). Conclusion: A multiparametric approach using flow-cytometry allows the reliable and sensitive measurement of both PGP expression and function simultaneously in single cells.Correspondence to:
Dr. M.R. Müller; Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, D-45122 Essen, Germany
Extended Abstract
10 Years CESAR Anticancer Drug Research – The 7th CESAR Annual Meeting 2009
L. Edler, D. Sehrt and M.E. Scheulen
Volume 48 p. 435 - 439
Abstract
10 Years CESAR Anticancer Drug Research – The 7th CESAR Annual Meeting 2009
L. Edler, D. Sehrt and M.E. Scheulen
Extended Abstract
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
D. Strumberg, L. Bergmann, U. Graeven, A. Hanauske, R. Lipp, J. Schuette, B. Schultheis, P. Scigalla, P. Urrea and M.E. Scheulen
Price
42.00 $
Volume 48 p. 470 - 472
Abstract
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
D. Strumberg, L. Bergmann, U. Graeven, A. Hanauske, R. Lipp, J. Schuette, B. Schultheis, P. Scigalla, P. Urrea and M.E. Scheulen
Extended Abstract
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler and K. Mross
Price
42.00 $
Volume 48 p. 473 - 475
Abstract
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler and K. Mross
Extended Abstracts
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents
H. Westekemper, M. Freistuehler, G. Anastassiou, G. Nareyeck, M. Zeschnigk, N. Bornfeld, K.-P. Steuhl, M.E. Scheulen and R.A. Hilger
Volume 49 p. 78 - 80
Abstract
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents
H. Westekemper, M. Freistuehler, G. Anastassiou, G. Nareyeck, M. Zeschnigk, N. Bornfeld, K.-P. Steuhl, M.E. Scheulen and R.A. Hilger
Extended Abstracts
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Volume 49 p. 88 - 90
Abstract
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Extended Abstracts
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
Volume 49 p. 96 - 98
Abstract
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
